Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis
Open Access
- 1 January 2014
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (4), 1095-106
- https://doi.org/10.3748/wjg.v20.i4.1095
Abstract
To investigate whether autologous dendritic cell (DC)-cytokine-induced killer (CIK) cell therapy is able to improve the therapeutic efficacy of chemotherapy in colon cancer. We conducted a systematic review of published papers from the sources of MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, the Wanfang Database, the China Science and Technology Periodical Database and China Journal Net. Published data were extracted independently by two authors using predefined database templates. The quality of the data from individual papers was also assessed. The effects of chemotherapy were compared with those of chemotherapy in combination with DC-CIK immunotherapy. The pooled analysis was performed using the data from random or fixed-effect models. Seven trials matched our inclusion criteria (n = 533). The overall analysis showed significant survival benefit [one-year overall survival (OS), P < 0.0001; two-year OS, P = 0.009; three-year OS, P = 0.002] in favor of DC-CIK immunotherapy combined with chemotherapy. Disease-free survival (DFS) rate was improved after the combination of DC-CIK immunotherapy and chemotherapy (one-year DFS, P < 0.0001; two-year DFS, P = 0.002; three-year DFS, P = 0.02). An improved overall response rate (P = 0.009) was also observed in patients who received DC-CIK therapy. Furthermore, the analysis of T-lymphocyte subsets in peripheral blood indicated that the number of CD4⁺ T cells significantly increased in the DC-CIK plus chemotherapy group (P < 0.05). The combination of DC-CIK immunotherapy and chemotherapy was superior in prolonging the survival time and enhancing immunological responses.Keywords
This publication has 32 references indexed in Scilit:
- T Cells Redirected to EphA2 for the Immunotherapy of GlioblastomaMolecular Therapy, 2013
- Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct MechanismsPublished by The American Association of Immunologists ,2013
- Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma: A Systemic ReviewPLOS ONE, 2012
- Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safetyExperimental Hematology & Oncology, 2012
- Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort studyCancer Immunology, Immunotherapy, 2012
- Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell CarcinomaJournal of Immunology Research, 2012
- Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal CancerAnnals of Surgical Oncology, 2010
- Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)Clinical Cancer Research, 2008
- Tumor Infiltrating T Lymphocytes in Colorectal CancerAnnals of Surgery, 2006
- Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer PatientsJournal of Clinical Oncology, 2005